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Abstract 
Review on NUAK1, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: ARK5 
HGNC (Hugo): NUAK1 
Location: 12q23.3 
Note: Details concerning the local order of the 
human NUAK1 locus can be found at ensembl.org.  
Human NUAK1 is found on chromosome 12 at 
position 106457118-106533811. Mouse NUAK1 is 
located on chromosome 10 at position 84370905- 
 
84440597. 
DNA/RNA 
Description 
The human NUAK1 gene is composed of seven 
exons and spans approximately 76.7 kbp of 
genomic DNA. 
Transcription 
The human NUAK1 gene encodes a 6828-bp 
mRNA. The coding region contains 1986 bp. Three 
short splice variants (547-569 bp) have been 
reported. 
Pseudogene 
No pseudogenes are known. 
 
The human NUAK1 gene has four splice variants. NUAK1-001 is composed of seven exons, which spans 6828 bp and encodes 
a 661-aa protein. NUAK1-003 is composed of two exons including one non-coding exon, which spans 547 bp and encodes a 
118-aa protein. NUAK1-004 is composed of five exons, which spans 560 bp and encodes a 152-aa protein. NUAK1-005 is 
composed of four exons including two non-coding exons, which spans 569 bp and encodes a 74-aa protein (see Ensembl 
ENSG00000074590). Open boxes indicate untranslated regions and shaded boxes indicate coding regions of the gene. 
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The catalytic domain of NUAK1 protein is located in the N-terminal at residues 55 to 306. K84 is an ATP binding site. T211 is 
phosphorylated by LKB1, which activates NUAK1 (Lizcano et al., 2004). W305 is required for binding of USP9X (Al-Hakim et al., 
2008). The GILK motif is a direct binding site for protein phosphatase PPP1CB (Zagorska et al., 2010). 
 
 
Protein 
Description 
NUAK1 protein consists of 661 amino acids and 
has a molecular weight of 74 kDa (Nagase et al., 
1998). NUAK1 contains a serine/threonine-protein 
kinase domain at its N-terminus that is conserved 
among AMPKalphas and AMPK-related kinases 
(AMPK-RKs) (Manning et al., 2002). The same as 
the AMPKalphas and most other AMPK-RKs, 
NUAK1 can be phosphorylated by tumor 
suppressor LKB1 at a conserved threonine residue 
(corresponding to Thr-211 in NUAK1) in the T-
loop of the catalytic domain, which activates the 
kinase activity of NUAK1 (Lizcano et al., 2004). 
The phosphorylation at Thr-211 is prevented by 
atypical Lys29/ Lys33-linked polyubiquitin chains, 
which can be removed by the de-ubiquitinating 
enzyme USP9X (Al-Hakim et al., 2008). 
Expression 
NUAK1 is preferentially expressed in highly 
oxidative tissues such as cerebrum, heart, and 
soleus muscle in human and mouse (Nagase et al., 
1998; Inazuka et al., 2012). In mouse 
embryogenesis, NUAK1 is prominently expressed 
in the neuroectoderm during neurulation, and in the 
cerebral cortex after the late embryonic stage 
(Ohmura et al., 2012; Courchet et al., 2013). In 
C2C12 mouse myoblasts, NUAK1 is increasingly 
expressed as the cells differentiate into myotubes 
(Niesler et al., 2007). The elevated expression of 
NUAK1 has been observed in clinical samples 
obtained from colorectal cancers, pancreatic 
cancers, hepatocellular carcinomas, gliomas, and 
angioimmunoblastic T-cell lymphomas (Kusakai et 
al., 2004a; Morito et al., 2006; Liu et al., 2012; Cui 
et al., 2013). 
Localisation 
NUAK1 is found in both the cytoplasm and 
nucleus. 
Function 
In HEK293 cells NUAK1 phosphorylates myosin 
phosphatase regulator MYPT1, which inhibits the 
activity of a MYPT1-PPP1CB phosphatase 
complex, enhancing cell detachment (Zagorska et  
al., 2010). In WI-38 fetal lung fibroblasts and 
MCF10A immortalized mammary epithelial cells 
NUAK1 phosphorylates the cyclin-dependent 
protein kinase regulator LATS1, which leads to 
destabilization of LATS1 and induces aneuploidy, 
resulting in cellular senescence in a cellular 
context-dependent manner (Humbert et al., 2010). 
In A549 lung adenocarcinoma cells NUAK1 acts as 
a transcriptional coactivator in a complex with 
LKB1 and a tumor suppressor p53, which induces 
cell cycle G1 arrest (Hou et al., 2011). 
In mice, NUAK1 is essential for closure of the 
ventral body wall in developing embryos (Hirano et 
al., 2006). NUAK1 and NUAK2 function in a 
complementary manner in the apical constriction 
and apico-basal elongation during early 
embryogenesis (Ohmura et al., 2012). The LKB1-
NUAK1 pathway regulates cortical axon branching 
by immobilizing mitochondria at nascent 
presynaptic sites during postnatal neuronal 
development (Courchet et al., 2013). NUAK1 has a 
role in the negative feedback regulation of insulin 
signaling, which is involved in glucose intolerance 
under high-fat diet conditions (Inazuka et al., 2012). 
In Caenorhabditis elegans, UNC-82, an ortholog of 
NUAK1 and NUAK2, maintains the organization 
of cytoskeletal structure during cell-shape change 
presumably through phosphorylation of myosin and 
paramyosin (Hoppe et al., 2010). 
Homology 
NUAK1 has the highest homology to NUAK2, 
whose similarity in the protein as a whole is 58%, 
and 82% in the kinase domain in human. Homo 
sapiens NUAK1 is 91% similar to Mus musculus 
NUAK1, 75% similar to Xenopus tropicalis 
NUAK1, and 65% similar to Caenorhabditis 
elegans UNC-82. 
Mutations 
Somatic 
A C-to-T transition at residues 661 in the NUAK1 
gene that results in a Pro-to-Ser substitution at 
codon 221 (P221S) has been found in tissue 
samples from human colorectal carcinomas and 
melanomas (Cancer Genome Atlas Network, 2012; 
Krauthammer et al., 2012). 
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Implicated in 
Glioma 
Disease 
Malignant gliomas are the most common type of 
primary brain tumor in adults. Glioma cells are 
highly proliferative, thereby readily invading 
surrounding brain structures. Thus, complete 
surgical resection is practically impossible (Stewart, 
2002). Glioma infiltration occurs through the 
activation of matrix metalloproteinases (MMPs). 
MMPs also exhibit a function in angiogenesis 
during tumor neovascularization (Forsyth et al., 
1999; Das et al., 2011). 
Prognosis 
Up-regulation of NUAK1 correlates with the World 
Health Organization grades of glioma (P < 0.001). 
High NUAK1 expression was markedly associated 
with reduced overall survival in grade II glioma (P 
< 0.01). The median survival time of patients with 
high NUAK1 expression (18.37 months, 95% 
confidence interval (CI): 15.95-20.04) was 
significantly shorter than that of patients with low 
NUAK1 expression level (43.80 months, 95% CI: 
23.47-48.36). The same conclusions were obtained 
in grades III and IV gliomas, indicating that 
NUAK1 is a valuable prognostic marker for glioma 
patients at all disease stages (Lu et al., 2013). 
Oncogenesis 
In several kinds of glioma cell lines, NUAK1 
promotes IGF-1-induced cell invasion, in which 
NUAK1 mediates cytoskeleton rearrangement 
through activation of LIMK1 and cofilin and 
activates MMP-2 and MMP-9 through production 
of MT1-MMP. Knockdown of NUAK1 reduces 
brain invasion in mice with glioma xenografts (Lu 
et al., 2013). 
Colorectal cancer (CRC) 
Disease 
CRC is the third leading cancer and the fourth 
leading cause of cancer deaths worldwide (Karsa et 
al., 2010). Various genetic changes, including APC 
mutation, mismatch repair defects, Wnt-activated 
alterations, RAF-mediated alterations, and p53 
alterations are concurrently observed in CRC. 
These mutations are interconnected to generate 
diverse pathways of colorectal tumorigenesis 
(Conlin et al., 2005; Roh et al., 2010). In addition, 
MMPs are overexpressed in colorectal tumors and 
involved in degrading components of the basement 
membrane during the progression of CRC (Collins 
et al., 2001; Dragutinovic et al., 2011). 
Prognosis 
Higher expression of NUAK1 is observed in 
advanced cases, and much higher expression is 
observed in liver metastases (Kusakai et al., 2004b; 
Roh et al., 2010). The expression of NUAK1 is 
closely associated with that of MMP-2 and MMP-9. 
Enhanced expression of NUAK1 is more frequent 
in tumors with RAF-mediated alterations (P = 
0.001) or crossover pathways carrying both 
APC/Wnt-activated and mismatch repair/RAF-
mediated alterations (P = 0.003) than those without 
them (Roh et al., 2010). 
Oncogenesis 
Higher NUAK1 expression is concordant with 
higher invasion activity in human colorectal cancer 
cell lines (Kusakai et al., 2004a; Kusakai et al., 
2004b). Knockdown of NUAK1 suppresses growth 
of CRC xenografts in mice (Liu et al., 2012). 
Hepatocellular carcinoma (HCC) 
Disease 
HCC is the fifth most common cancer and the third 
most frequent cause of death of cancer worldwide. 
Liver resection is considered to be the mainly 
curative therapy for HCC, with about 50-70% 5-
year overall survival after curative hepatectomy. 
However, the postoperative recurrence rate remains 
as high as 70-83.7% (Bruix and Sherman, 2005; 
Llovet, 2005). 
Prognosis 
In HCC, the high expression of NUAK1 is related 
to tumor size (P=0.005), histological differentiation 
(P=0.047), tumor stage (P=0.005), and a 
significantly poor prognosis. Multivariate analysis 
identified the level of NUAK1 expression as an 
independent predictor of the overall survival rate of 
patients with HCC (Cui et al., 2013). 
Oncogenesis 
Several cancer cell lines including HCC which are 
expressed oncogenic levels of MYC establish a 
dependence on NUAK1 for maintaining metabolic 
homeostasis and for cell survival, in which NUAK1 
restrains mTOR signaling via suppression of 
proteasomal degradation of AMPKbeta and also 
maintains expression of mitochondrial respiratory 
chain complexes. Knockdown of NUAK1 prevents 
tumorigenesis in MYC-driven mouse models of 
HCC. Depletion of NUAK1 after tumorigenesis 
also suppresses tumor growth and provides a 
survival advantage to the mice (P < 0.01) (Liu et 
al., 2012). 
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